When Does Imbruvica Go Generic?

Generic versions of Imbruvica reach the market when a manufacturer wins FDA approval of an Abbreviated New Drug Application (ANDA) proving bioequivalence to the brand. ANDA filers must address every Orange Book-listed patent; certifying that a patent is invalid or not infringed (a "Paragraph IV" certification) triggers Hatch-Waxman litigation and a 30-month FDA stay. The first filer to clear that gauntlet earns 180 days of generic exclusivity as the sole low-cost competitor — the period in which it captures the most margin before prices collapse. Because entry is blocked until the LATEST relevant patent clears (this portfolio runs to 2042), the practical generic date is usually later than the earliest expiration alone implies.

Because Imbruvica's earliest patent expiry is more than three years out, generic competition is not imminent. ANDA filings can occur as early as four years after NDA approval (the so-called "5-year exclusivity wall"), but actual market entry is gated by the latest unexpired patent. For clinicians and payers, the planning horizon for generic substitution on Imbruvica is 2032 at the earliest.

Once generic Imbruvica enters the market, brand prices historically fall 50–90% within two years as multiple ANDA holders compete. The single biggest drop typically arrives after the first filer's 180-day exclusivity ends and additional generics flood in. Patients should ask their pharmacist about generic substitution and compare cash prices on GoodRx and Mark Cuban's Cost Plus Drugs once a generic is approved.

The authoritative source for which generic versions are actually approved is the FDA Orange Book, which lists every ANDA-approved equivalent and the patents an applicant had to clear. To compare cash prices once a generic lands, check GoodRx and Mark Cuban's Cost Plus Drugs. Underlying patent expiration data on this page is sourced from USPTO PatentsView.

Imbruvica is protected by 5 US patents, a mid-sized portfolio that is typical for an established branded drug in mid-lifecycle. The portfolio likely combines a primary composition-of-matter patent (the strongest form of protection) with a layer of formulation, dosing, and method-of-use patents that extend exclusivity beyond the original composition expiry — a common strategy known as "patent layering" or, less charitably, "evergreening."

Imbruvica patent rights are held across 2 entities: Pharmacyclics LLC, AbbVie Inc.. Multi-assignee portfolios usually reflect co-development partnerships, licensing splits between an originator and a marketing partner, or assignments made during corporate restructurings. Multi-party ownership can complicate generic entry — a challenger may need to clear patents from each holder separately, and settlements are harder to reach.

The Imbruvica portfolio scores 71/100 (Grade B, "strong") on the PatentCliff Strength index. The strongest signal is portfolio size (100/100), and the weakest is technology diversity (23/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.

Looking at the 5 dated patents in the portfolio, the largest cluster (3 patents) falls in the "5–10 years (2032–2036)" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.

The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.